ImmunoGen Inc (IMGN)

US45253H1014 - Common Stock

31.23  0 (0%)

After market: 31.24 +0.01 (+0.03%)

News Image
6 days ago - Bloomberg

AbbVie Selling $15 Billion Bonds to Buy ImmunoGen, Cerevel

Pharmaceutical giant AbbVie Inc. is selling around $15 billion of bonds in the US investment-grade market on Thursday to help fund its acquisitions of ImmunoGen Inc. and Cerevel Therapeutics Holdings Inc., adding to a recent rush of buyout financings.

News Image
6 days ago - Bloomberg

AbbVie Eyes Selling at Least $13 Billion of Bonds to Fund M&A

Pharmaceutical giant AbbVie Inc. is looking to sell at least $13 billion of corporate bonds to help fund its acquisitions of ImmunoGen Inc. and Cerevel Therapeutics Holdings Inc., according to people with knowledge of the matter.

News Image
16 days ago - Seeking Alpha

AbbVie revises Q1 earnings outlook as ImmunoGen deal closes (NYSE:ABBV)

AbbVie updates its earnings outlook for Q1 2024, reflecting a dilutive impact from the completed acquisition of ImmunoGen.

News Image
16 days ago - AbbVie

AbbVie Completes Acquisition of ImmunoGen

Adds flagship antibody-drug conjugate (ADC) ELAHEREĀ® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRĪ±) positive platinum-resistant ovarian...

News Image
18 days ago - Investor's Business Daily

Amicus Therapeutics Stock Sees Improved Relative Strength Rating

In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday.

News Image
20 days ago - Seeking Alpha

ImmunoGen stock spikes as HSR period for AbbVie deal expires (NASDAQ:IMGN)

ImmunoGen's (IMGN) all-cash deal acquisition by AbbVie (ABBV) is set to be completed next week after the expiration of the Hart-Scott-Rodino waiting period. Read more here.

News Image
21 days ago - InvestorPlace

3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List

These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry.

News Image
21 days ago - InvestorPlace

7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024

Unveil these standout Russell 2000 stocks, meticulously picked to harness the potential of the evolving market landscape in the 2024 surge.

News Image
22 days ago - Investor's Business Daily

Madrigal Pharmaceuticals Stock Shows Rising Relative Strength

A Relative Strength Rating upgrade for Madrigal Pharmaceuticals shows improving technical performance.

News Image
24 days ago - Seeking Alpha

Pharma hunt antibody-drug conjugates in China (NYSE:PFE)

China has become a dominant player in the antibody-drug conjugate (ADC) race, attracting Western pharmaceutical companies for partnerships. Read more here.

News Image
a month ago - Seeking Alpha

AbbVie Q4 in focus as Humira patent cliff reaches one year

AbbVie is set to report its Q4 2023 results amid one year anniversary of biosimilar competition against its blockbuster arthritis therapy Humira. Read more here.

News Image
a month ago - BusinessInsider

AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures

AbbVie's growth outlook in 2024 as William Blair upgrades, highlighting strong performance in Humira erosion management, strategic acquisitions, and a 3.8% dividend yield.

News Image
a month ago - Market News Video

IMGN August 16th Options Begin Trading

News Image
a month ago - TheNewswire.com

Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate

New York, Jan. 29, 2024 - (Plato Data) -- Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug conjugate (ADC) CRB-701 in a Phase 1 trial. Citing a December data cut in patients with cancers expressing a tumor-associated antigen called nectin-4, Corbus (CRBP) said that CRB-701 led to an objective response rate (ORR) of 43%, including three partial responses.

News Image
a month ago - Investor's Business Daily

Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating

Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

News Image
a month ago - InvestorPlace

7 Dividend Aristocrats That Will Pay You for Years to Come

If you're looking for a consistent income, consider some of these top Dividend Aristocrats to buy and hold in 2024.

News Image
a month ago - Investor's Business Daily

Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83

On Thursday, Ultragenyx Pharm stock just cleared that 80 or higher RS Rating benchmark with an upgrade from 75 to 83.

News Image
a month ago - Investor's Business Daily

Cassava Sciences Stock Continues Showing Rising Relative Strength

Cassava Sciences sees its Relative Strength Rating move into the elite 90-plus level.

News Image
2 months ago - Kuehn Law, PLLC

Kuehn Law Encourages PXD, IMGN, HA and ICVX Investors to Contact Law Firm

/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...

News Image
2 months ago - The Motley Fool

Is AbbVie Stock a Buy Now?

The company is grappling with losing Humira's patent protection in 2023.

News Image
2 months ago - Investor's Business Daily

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

News Image
2 months ago - Halper Sadeh LLP

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WAVD, ROVR, HA, IMGN

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

News Image
2 months ago - Kuehn Law, PLLC

Kuehn Law Encourages CERE, HA, IMGN, and WAVD Investors to Contact Law Firm

/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...

News Image
2 months ago - InvestorPlace

3 Biotech Stocks Set for Breakthroughs in 2024

With groundbreaking advancements in new medicine and science, 2024 holds a promising future for these biotech stocks.

News Image
2 months ago - Seeking Alpha

What's in store for biotech M&A and IPOs in 2024? (NYSE:BMY)

Biotech M&A ended 2023 with a bang, but can investors expect the party to continue into 2024? And will the IPO market finally bounce back? Read more here.

News Image
2 months ago - Halper Sadeh LLP

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EAR, IMGN, CVLY

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

News Image
2 months ago - The Motley Fool

AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's Why

The acquisition fills an immediate need with some extras to boot.

News Image
2 months ago - InvestorPlace

3 Stocks at the Forefront of Medical Innovation

Boring businesses and industries typically show new faces when technology comes around; today, these biotech stocks are leading the way.

News Image
2 months ago - Seeking Alpha

M&A activity expected to pick up in 2024, bankers say

Merger and acquisition activity is set to rise in the coming year as borrowing becomes easier and companies are undeterred by antitrust regulators, signaling...

News Image
2 months ago - Investor's Business Daily

Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade

On Thursday, Tarsus Pharmaceuticals stock reached a key technical milestone, seeing its Relative Strength Rating jump to 91 from 84.